SGLT2 inhibitors associated with reduced heart failure and mortality after heart attack in preserved ejection fraction patients
This retrospective cohort study of 230 AMI-PCI patients with preserved ejection fraction (LVEF ≥50%) compared outcomes in those prescribed SGLT2 inhibitors versus no SGLT2 inhibitors. After propensity score matching, SGLT2i use was associated with lower rates of new-onset heart failure (6.09% vs 15.65%), all-cause mortality (3.48% vs 10.43%), cardiovascular mortality (1.74% vs 9.57%), and MACE (7.83% vs 18.26%) over at least 18 months follow-up.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 15, 2026 · Discovered: Sep 22, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 230
- Duration
- 18 months
- Population
- Patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with preserved left ventricular ejection fraction (LVEF ≥ 50%) and no prior heart failure history
- Primary outcome
- Occurrence of new-onset heart failure (HF) events
- Effect size
- For new-onset HF: 6.09% vs. 15.65%, P=0.020; for all-cause mortality: 3.48% vs. 10.43%, P=0.038; for cardiovascular mortality: 1.74% vs. 9.57%, P=0.010; for MACE: 7.83% vs. 18.26%, P=0.019. Multivariable Cox regression: HR 0.583 (95% CI, 0.371-0.916; P=0.017)
- Significance
- Significant
- Journal
- American journal of translational research
- Published
- Aug 15, 2026
Sources
Primary source
- American journal of translational research ↗Peer reviewed
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.